Results 11 to 20 of about 16,205 (199)

Thiopurine S -methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs [PDF]

European Journal of Clinical Pharmacology, 2018
Objective: More than 11% of the Caucasian population are heterozygous or homozygous carriers of thiopurine S-methyltransferase (TPMT) mutants and are at risk for toxic side effects when treated with thiopurine drugs.
Fried, M., Kullak-Ublick, G., Rammert, C., Rentsch, K., von Eckardstein, A., Wusk, Barbara   +5 more
core   +4 more sources

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. [PDF]

Clin Pharmacol Ther
Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard ...
Maillard M, Schwab M, Whirl-Carrillo M, Moyer AM, Suarez-Kurtz G, Pui CH, Stein CM, Klein TE, Spahn C, Kwon S, Hartono JL, de Boer NK, Ahmad T, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ.   +18 more
europepmc   +2 more sources

Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations

Frontiers in Pharmacology, 2021
Backgound: The high incidence of thiopurine-induced myelosuppression in Asians is known to be attributable to genetic variation in thiopurine metabolism.
Kanyarat Khaeso, Sariya Udayachalerm, Patcharee Komvilaisak, Su-on Chainansamit, Kunanya Suwannaying, Napat Laoaroon, Pitchayanan Kuwatjanakul, Nontaya Nakkam, Chonlaphat Sukasem, Chonlaphat Sukasem, Apichaya Puangpetch, Apichaya Puangpetch, Wichittra Tassaneeyakul, Nathorn Chaiyakunapruk   +13 more
doaj   +1 more source

Thiopurine pathway [PDF]

Pharmacogenetics and Genomics, 2010
The thiopurine drugs are purine antimetabolites widely used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g. Crohn’s disease and rheumatoid arthritis) and of organ transplant recipients. As inactive prodrugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) and azathioprine require intracellular activation, catalyzed by ...
Gianluigi Zaza, Meyling Cheok, Natalia Krynetskaia, Caroline Thorn, STOCCO, GABRIELE, Joan M. Hebert, Howard McLeod, Richard M. Weinshilboum, Mary V. Relling, William E. Evans, Teri E. Klein, Russ B. Altman   +11 more
openaire   +7 more sources

Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. [PDF]

PLoS ONE, 2015
Thiopurine drugs are well established treatments in the management of inflammatory bowel disease (IBD), but their use is limited by significant adverse drug reactions (ADRs).
Yue-Ping Liu, Hai-Yan Wu, Xiang Yang, Han-Qing Xu, Yong-Chuan Li, Da-Chuan Shi, Jun-Fu Huang, Qing Huang, Wei-Ling Fu   +8 more
doaj   +1 more source

A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients

Scientific Reports, 2022
The thiopurine derivatives azathioprine (AZA), mercaptopurine (MP) and tioguanine (TG) remain standard treatment of inflammatory bowel disease (IBD). The immune suppressive effect of thiopurines is primarily based on blocking the Ras-related C3 botulinum
Debbie S. Deben, Rob H. Creemers, Arjan J. van Adrichem, Roosmarie Drent, Audrey H. H. Merry, Mathie P. G. Leers, Adriaan A. van Bodegraven, Dennis R. Wong   +7 more
doaj   +1 more source

The Inhibitory Effects of 6-Thioguanine and 6-Mercaptopurine on the USP2a Target Fatty Acid Synthase in Human Submaxillary Carcinoma Cells

Frontiers in Oncology, 2021
Overexpression of the deubiquitinase USP2a leads to stabilization of fatty acid synthase (FAS), the levels of which are often elevated in aggressive human cancers.
Chiao-Pei Cheng, Shu-Ting Liu, Yi-Lin Chiu, Shih-Ming Huang, Ching-Liang Ho   +4 more
doaj   +1 more source

A primary hepatic lymphoma in a patient with Crohn's disease receiving thiopurine and anti-TNF therapy: a case report

Future Science OA, 2023
Primary hepatic lymphoma is a rare variant of non-Hodgkin's lymphoma with an incidence of 0.016% of all non-Hodgkin lymphomas. The most common histologic subtype is large diffuse B-cell lymphoma.
Salma Merhaben, Shema Ayadi, Monia Tangour, Nadia Boujelbene, Rayfa Ghariani, Leila Mouelhi, Fathi Merhaben   +6 more
doaj   +1 more source

Usefulness and difficulties with the thiopurine pharmacogenomic NUDT15 genotyping test: Analysis of real-world data in Japan

Journal of Pharmacological Sciences, 2023
The usefulness of NUDT15 genotyping as a pharmacogenomic test for thiopurine has been established. The first such test developed to date, NUDT15 genotyping was approved for reimbursement in Japan in February 2019 for all indicated patients.
Yoichi Kakuta, Motohiro Kato, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Masatake Kuroha, Hisashi Shiga, Yoshitaka Kinouchi, Atsushi Masamune   +8 more
doaj   +1 more source

Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with heterozygosity [PDF]

Intestinal Research, 2022
Background/Aims Thiopurines are key drugs for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Recently, NUDT15 polymorphism (R139C, c.415C > T) has been shown to be associated with thiopurine-induced adverse ...
Takato Maeda, Hirotake Sakuraba, Hiroto Hiraga, Shukuko Yoshida, Yoichi Kakuta, Hidezumi Kikuchi, Shogo Kawaguchi, Keisuke Hasui, Tetsuya Tatsuta, Daisuke Chinda, Tatsuya Mikami, Shinsaku Fukuda   +11 more
doaj   +1 more source